Trial Profile
A study of Mipsagargin in combination with Sorafenib (Nexavar®) in patients with advanced hepatocellular carcinoma (HCC), or liver cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Mipsagargin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 02 Jun 2017 New trial record
- 30 May 2017 According to an Inspyr Therapeutics media release, the company is finalising the trial design.